Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Inulin as a Delivery Vehicle for Targeting Colon-Specific Cancer

Author(s): Swati Chadha, Arun Kumar*, Shambhavi Ashwini Srivastava, Tapan Behl and Rishu Ranjan

Volume 17, Issue 8, 2020

Page: [651 - 674] Pages: 24

DOI: 10.2174/1567201817666200527133719

Price: $65

Abstract

Natural polysaccharides, as well as biopolymers, are now days widely developed for targeting colon cancer using various drug delivery systems. Currently, healing conformations are being explored that can efficiently play a multipurpose role. Owing to the capability of extravagance colonic diseases with the least adverse effects, biopolymers for site specific colon delivery have developed an increased curiosity over the past decades. Inulin (INU) was explored for its probable application as an entrapment material concerning its degradation by enzymes in the colonic microflora and its drug release behavior in a sustained and controlled manner. INU is a polysaccharide and it consists of 2 to 1 linkage having an extensive array of beneficial uses such as a carrier for delivery of therapeutic agents as an indicative/investigative utensil or as a dietary fiber with added well-being aids. In the main, limited research, as well as information, is available on the delivery of therapeutic agents using inulin specifically for colon cancer because of its capability to subsist in the stomach’s acidic medium. This exceptional steadiness and robustness properties are exploited in numerous patterns to target drugs securely for the management of colonic cancer, where they effectively act and kills colonic tumor cells easily. In this review article, recent efforts and inulin-based nano-technological approaches for colon cancer targeting are presented and discussed.

Keywords: Inulin, polysaccharides, colon cancer, polymeric drug delivery systems, polysaccharide, dietary fiber.

« Previous Next »
Graphical Abstract

[1]
Beerenwinkel, N.; Antal, T.; Dingli, D.; Traulsen, A.; Kinzler, K.W.; Velculescu, V.E.; Vogelstein, B.; Nowak, M.A. Genetic progression and the waiting time to cancer. PLOS Comput. Biol., 2007, 3(11) e225
[http://dx.doi.org/10.1371/journal.pcbi.0030225] [PMID: 17997597]
[2]
Winawer, S.J. The history of colorectal cancer screening: a personal perspective. Dig. Dis. Sci., 2015, 60(3), 596-608.
[http://dx.doi.org/10.1007/s10620-014-3466-y] [PMID: 25599958]
[3]
World Health Organization. Global Health Observatory; World Health Organization: Geneva, 2018. who.int/gho/database/
[4]
Smith, R.E.; Renaud, R.C.; Hoffman, E. Colorectal cancer market. Nat. Rev. Drug Discov., 2004, 3(6), 471-472.
[http://dx.doi.org/10.1038/nrd1419] [PMID: 15214331]
[5]
Gersten, O.; Wilmoth, J.R. The cancer transition in Japan since 1951. Demogr. Res., 2002, 7, 271-306.
[http://dx.doi.org/10.4054/DemRes.2002.7.5]
[6]
Bray, F.; Soerjomataram, I. Transitions in human development and the global cancer burden.World Cancer Report 2014 ; Stewart, B.W.; Wild, C.P., Eds.; IARC Press: Lyon, 2014, pp. 42-55.
[7]
Maule, M.; Merletti, F. Cancer transition and priorities for cancer control. Lancet Oncol., 2012, 13(8), 745-746.
[http://dx.doi.org/10.1016/S1470-2045(12)70268-1] [PMID: 22846827]
[8]
Wolpin, B.M.; Mayer, R.J. Systemic treatment of colorectal cancer. Gastroenterology, 2008, 134(5), 1296-1310.
[http://dx.doi.org/10.1053/j.gastro.2008.02.098] [PMID: 18471507]
[9]
Mishra, J.; Drummond, J.; Quazi, S.H.; Karanki, S.S.; Shaw, J.J.; Chen, B.; Kumar, N. Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit. Rev. Oncol. Hematol., 2013, 86(3), 232-250.
[http://dx.doi.org/10.1016/j.critrevonc.2012.09.014] [PMID: 23098684]
[10]
Kahouli, I.; Tomaro-Duchesneau, C.; Prakash, S. Probiotics in Colorectal Cancer (CRC) with emphasis on mechanisms of action and current perspectives. J. Med. Microbiol., 2013, 62(Pt 8), 1107-1123.
[http://dx.doi.org/10.1099/jmm.0.048975-0] [PMID: 23558140]
[11]
Husemann, T.; Flückiger, F.A. Pharmacographia. A history of the principal drugs of vegetable origin, met with in Great Britain and British India. Arch. Pharm., 1880, 216, 235-238.
[12]
Coussement, P.A. Inulin and oligofructose: safe intakes and legal status. J. Nutr., 1999, 129(7), S1412-S1417.
[http://dx.doi.org/10.1093/jn/129.7.1412S] [PMID: 10395609]
[13]
Niness, K.R. Inulin and oligofructose: what are they? Zucker., 1952, 5, 30-33.
[14]
Verraest, D.L.; Peters, J.A.; Batelaan, J.G.; van Bekkum, H. Carboxymethylation of inulin. Carbohydr. Res., 1995, 271(1), 101-112.
[http://dx.doi.org/10.1016/0008-6215(95)00028-R] [PMID: 7648576]
[15]
Kruger, C.L. Generally Recognized as Safe (GRAS) notification for Frutafit, Food and Drug Administration: Arlington, VA, 2002.
[16]
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*stat database:. mortality-all cod, aggregated with state, total US (1969-2010) National Cancer Institute, division of cancer control and population sciences, surveillance research program. Cancer Statistics Branch, 2013.
[17]
Surveillance, E.; Results, E. (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Public Use, Nov. 2011 Sub (1973-2010)-Linked to County Attributes-Total US, 1969-2011 Counties; National Cancer Institute, division of cancer control and population sciences; Surveillance Research Program, Cancer Statistics Branch: Bethesda, MD, 2013.
[18]
Maxwell, P.; Freddie, D.; Jacques, F.; Paola, P. Estimating the world cancer burden: Globocan2000. Int. J. Cancer, 2001, 94(2), 153-156.
[19]
United States Cancer Statistics:. 1999-2008 incidence and mortality web-based report. Atlanta: Centres for Disease Control and Prevention; National Cancer Institute.CDC (Centres for Disease Control and Prevention); , 2012.
[20]
Lindsey, A.; Torre, MSPH.; Freddie, B.R.; Siegel, MPH.; Jacques, F.; JoannieLortet-Tieulent, M.E.; Ahmedin, J. On global cancer statistics, 2012. Cancer J. Clin., 2015, 65, 87-108.
[21]
Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin., 2014, 64(1), 9-29.
[http://dx.doi.org/10.3322/caac.21208] [PMID: 24399786]
[22]
Chen, H.S.; Portier, K.; Ghosh, K.; Naishadham, D.; Kim, H.J.; Zhu, L.; Pickle, L.W.; Krapcho, M.; Scoppa, S.; Jemal, A.; Feuer, E.J. Predicting US- and state-level cancer counts for the current calendar year: part I: evaluation of temporal projection methods for mortality. Cancer, 2012, 118(4), 1091-1099.
[http://dx.doi.org/10.1002/cncr.27404] [PMID: 22228565]
[23]
Zhu, L.; Pickle, L.W.; Ghosh, K.; Naishadham, D.; Portier, K.; Chen, H.S.; Kim, H.J.; Zou, Z.; Cucinelli, J.; Kohler, B.; Edwards, B.K.; King, J.; Feuer, E.J.; Jemal, A. Predicting US- and state-level cancer counts for the current calendar year: part II: evaluation of spatiotemporal projection methods for incidence. Cancer, 2012, 118(4), 1100-1109.
[http://dx.doi.org/10.1002/cncr.27405] [PMID: 22228583]
[24]
Atlanta, G.A. Centres for disease control and prevention, National centre for chronic disease prevention and health promotion. 2012 Behavioural Risk Factor Surveillance System (BRFSS) Public Use Data Tapes; Centres for Disease Control and Prevention, 2013.
[25]
Surveillance Research Program, National Cancer Institute. SEER* Stat software. Version 8.1.2; National Cancer Institute: Bethesda, MD, 2013.
[26]
World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR). Continuous Update Project Report: Diet, Nutrition, Physical Activity and Colorectal Cancer 2016. Revised 2018; World Cancer Research Fund International: London, 2018.
[27]
Boyle, P.; Langman, J.S. ABC of colorectal cancer: epidemiology. BMJ, 2000, 321(7264), 805-808.
[http://dx.doi.org/10.1136/bmj.321.7264.805] [PMID: 11009523]
[28]
Surveillance, E.; Results, E. (SEER) Program SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence-CiNA Analytic File, 1995-2010, for Expanded Races, custom file with county, ACS Facts & Figures projection project, North American Association of Central Cancer Registries, National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch: Bethesda, MD. 2013.
[29]
Dobre, M.; Dinu, D.E.; Panaitescu, E. B??rlŽŸ, R.D.; Iosif, C.I.; Boeriu, M.; Constantinoiu, S.; Ivan, R.N.; Ardeleanu, C.M.; Costache, M. KRAS gene mutations - prognostic factor in colorectal cancer? Rom. J. Morphol. Embryol., 2015, 56(2), S671-S678.
[PMID: 26429158]
[30]
Center, M.M.; Jemal, A.; Smith, R.A.; Ward, E. Worldwide variations in colorectal cancer. CA Cancer J. Clin., 2009, 59(6), 366-378.
[http://dx.doi.org/10.3322/caac.20038] [PMID: 19897840]
[31]
Bosetti, C.; Rodríguez, T.; Chatenoud, L.; Bertuccio, P.; Levi, F.; Negri, E.; La Vecchia, C. Trends in cancer mortality in Mexico, 1981-2007. Eur. J. Cancer Prev., 2011, 20(5), 355-363.
[http://dx.doi.org/10.1097/CEJ.0b013e32834653c9] [PMID: 21464718]
[32]
Freddie, B.; Jacques, F.; Isabelle, S. Global cancer statistics GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries., 2018.
[33]
Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater., 2013, 12(11), 991-1003.
[http://dx.doi.org/10.1038/nmat3776] [PMID: 24150417]
[34]
Beringer, A.; Wenger, R. Inulin in der ernahrung des diabetikers. Dutch. Z. Verdauungs Stofwechselkrankh. J. Nutr., 1995, 15, 268-272.
[35]
Hoebregs, H. Fructans in foods and food products, ion-exchange chromatographic method: collaborative study. Joint commission of biochemical nomenclature abbreviated terminology of oligosaccharide chains. J. Biol. Chem., 1982, 257, 1029-1037.
[36]
Roberfroid, M.B.; Van Loo, J.A.; Gibson, G.R. The bifidogenic nature of chicory inulin and its hydrolysis products. J. Nutr., 1998, 128(1), 11-19.
[http://dx.doi.org/10.1093/jn/128.1.11] [PMID: 9430596]
[37]
Li, F.Y.; Lai, M.D. Colorectal cancer, one entity or three. J. Zhejiang Univ. Sci. B, 2009, 10(3), 219-229.
[http://dx.doi.org/10.1631/jzus.B0820273] [PMID: 19283877]
[38]
Murphy, N.; Ward, H.A.; Jenab, M.; Rothwell, J.A.; Boutron-Ruault, M.C.; Carbonnel, F.; Kvaskoff, M.; Kaaks, R.; Kühn, T.; Boeing, H.; Aleksandrova, K.; Weiderpass, E.; Skeie, G.; Borch, K.B.; Tjønneland, A.; Kyrø, C.; Overvad, K.; Dahm, C.C.; Jakszyn, P.; Sánchez, M.J.; Gil, L.; Huerta, J.M.; Barricarte, A.; Quirós, J.R.; Khaw, K.T.; Wareham, N.; Bradbury, K.E.; Trichopoulou, A.; La Vecchia, C.; Karakatsani, A.; Palli, D.; Grioni, S.; Tumino, R.; Fasanelli, F.; Panico, S.; Bueno-de-Mesquita, B.; Peeters, P.H.; Gylling, B.; Myte, R.; Jirström, K.; Berntsson, J.; Xue, X.; Riboli, E.; Cross, A.J.; Gunter, M.J. Heterogeneity of colorectal cancer risk factors by anatomical sub site in 10 European countries: a multinational cohort study. Clin. Gastroenterol. Hepatol., 2019, 17(7), 1323-1331.e6.
[http://dx.doi.org/10.1016/j.cgh.2018.07.030] [PMID: 30056182]
[39]
Wei, E.K.; Giovannucci, E.; Wu, K.; Rosner, B.; Fuchs, C.S.; Willett, W.C.; Colditz, G.A. Comparison of risk factors for colon and rectal cancer. Int. J. Cancer, 2004, 108(3), 433-442.
[http://dx.doi.org/10.1002/ijc.11540] [PMID: 14648711]
[40]
Edge, S.; Byrd, D.R.; Compton, C.C.; Fritz, A.G.; Greene, F.L.; Trotti, A. Colon and rectum.Springer; Cancer Staging Manual, A.J.C.C., Ed.; NY, USA, 2014, pp. 143-164.
[41]
Sobin, L.H.; Gospodarowicz, M.K.; Wittekind, C. Colon and rectum. In: TNM classification of malignant tumors. (Eds).Int. Union Against Cancer, Wiley-Blackwell Chichester, Sussex, UK, -NJ, USA; , 2010, p. 309.
[http://dx.doi.org/10.1002/9780471420194.tnmc13.pub2]
[42]
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature, 2012, 487(7407), 330-337.
[http://dx.doi.org/10.1038/nature11252] [PMID: 22810696]
[43]
Chabner, B.A.; Roberts, T.G. Jr. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer, 2005, 5(1), 65-72.
[http://dx.doi.org/10.1038/nrc1529] [PMID: 15630416]
[44]
Dow, L.E.; Rourke, K.P.; Simon, J.; Tschaharganeh, D.F.; van Es, J.H.; Clevers, H.; Lowe, S.W. APC restoration promotes cellular differentiation and re-establishes crypt homeostasis in colorectal cancer. Cell, 2015, 161(7), 1539-1552.
[http://dx.doi.org/10.1016/j.cell.2015.05.033] [PMID: 26091037]
[45]
Armaghany, T.; Wilson, J.D.; Chu, Q.; Mills, G. Genetic alterations in colorectal cancer. Gastrointest. Cancer Res., 2012, 5(1), 19-27.
[PMID: 22574233]
[46]
Kedrin, D.; Gala, M.K. Genetics of the serrated pathway to colorectal cancer. Clin. Transl. Gastroenterol., 2015, 6, e84
[http://dx.doi.org/10.1038/ctg.2015.12] [PMID: 25856207]
[47]
Leggett, B.; Whitehall, V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology, 2010, 138(6), 2088-2100.
[http://dx.doi.org/10.1053/j.gastro.2009.12.066] [PMID: 20420948]
[48]
Gabriel, A.; Kune, A. The nutritional causes of colorectal cancer: an introduction to the Melbourne study by Department of Surgery, University of Melbourne, Repatriation General Hospital, Heidelberg, Victoria, Australia, 2009.
[49]
Ma, Y.; Yang, Y.; Wang, F.; Zhang, P.; Shi, C.; Zou, Y.; Qin, H. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One, 2013, 8(1) e53916
[http://dx.doi.org/10.1371/journal.pone.0053916] [PMID: 23349764]
[50]
Moore, H.G. Colorectal cancer: what should patients and families be told to lower the risk of colorectal cancer? Surg. Oncol. Clin. N. Am., 2010, 19(4), 693-710.
[http://dx.doi.org/10.1016/j.soc.2010.06.002] [PMID: 20883947]
[51]
Lieberman, D.A.; Prindiville, S.; Weiss, D.G.; Willett, W. VA cooperative study group 380. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA, 2003, 290(22), 2959-2967.
[http://dx.doi.org/10.1001/jama.290.22.2959] [PMID: 14665657]
[52]
Lichtenstein, P.; Holm, N.V.; Verkasalo, P.K.; Iliadou, A.; Kaprio, J.; Koskenvuo, M.; Pukkala, E.; Skytthe, A.; Hemminki, K. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med., 2000, 343(2), 78-85.
[http://dx.doi.org/10.1056/NEJM200007133430201] [PMID: 10891514]
[53]
International Agency for Research on Cancer (IARC) Globocan 2018. Cancer Fact Sheets-. Colorectal Cancer, 2018.
[54]
Boyle, P.; Zaridze, D.G.; Smans, M. Descriptive epidemiology of colorectal cancer. Int. J. Cancer, 1985, 36(1), 9-18.
[http://dx.doi.org/10.1002/ijc.2910360103] [PMID: 2991145]
[55]
Janout, V. Kollo¬rov¬, H. Epidemiology of colorectal cancer. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2001, 145(1), 5-10.
[http://dx.doi.org/10.5507/bp.2001.001] [PMID: 12415635]
[56]
Islami, F.; Goding Sauer, A.; Miller, K.D.; Siegel, R.L.; Fedewa, S.A.; Jacobs, E.J.; McCullough, M.L.; Patel, A.V.; Ma, J.; Soerjomataram, I.; Flanders, W.D.; Brawley, O.W.; Gapstur, S.M.; Jemal, A. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J. Clin., 2018, 68(1), 31-54.
[http://dx.doi.org/10.3322/caac.21440] [PMID: 29160902]
[57]
Johnson, I.T.; Lund, E.K. Review article: nutrition, obesity and colorectal cancer. Aliment. Pharmacol. Ther., 2007, 26(2), 161-181.
[http://dx.doi.org/10.1111/j.1365-2036.2007.03371.x] [PMID: 17593063]
[58]
Larsson, S.C.; Wolk, A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int. J. Cancer, 2006, 119(11), 2657-2664.
[http://dx.doi.org/10.1002/ijc.22170] [PMID: 16991129]
[59]
Santarelli, R.L.; Pierre, F.; Corpet, D.E. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr. Cancer, 2008, 60(2), 131-144.
[http://dx.doi.org/10.1080/01635580701684872] [PMID: 18444144]
[60]
Willett, W.C. Diet and cancer: an evolving picture. JAMA, 2005, 293(2), 233-234.
[http://dx.doi.org/10.1001/jama.293.2.233] [PMID: 15644551]
[61]
Sinha, R. An epidemiologic approach to studying heterocyclic amines. Mutat. Res., 2002, 506-507, 197-204.
[http://dx.doi.org/10.1016/S0027-5107(02)00166-5] [PMID: 12351159]
[62]
Campbell, P.T.; Cotterchio, M.; Dicks, E.; Parfrey, P.; Gallinger, S.; McLaughlin, J.R. Excess body weight and colorectal cancer risk in Canada: associations in subgroups of clinically defined familial risk of cancer. Cancer Epidemiol. Biomarkers Prev., 2007, 16(9), 1735-1744.
[http://dx.doi.org/10.1158/1055-9965.EPI-06-1059] [PMID: 17855691]
[63]
Lee, K.J.; Inoue, M.; Otani, T.; Iwasaki, M.; Sasazuki, S.; Tsugane, S. JPHC study group. Physical activity and risk of colorectal cancer in Japanese men and women: the Japan public health center-based prospective study. Cancer Causes Control, 2007, 18(2), 199-209.
[http://dx.doi.org/10.1007/s10552-006-0098-3] [PMID: 17206529]
[64]
de Jong, A.E.; Morreau, H.; Nagengast, F.M.; Mathus-Vliegen, E.M.; Kleibeuker, J.H.; Griffioen, G.; Cats, A.; Vasen, H.F. Prevalence of adenomas among young individuals at average risk for colorectal cancer. Am. J. Gastroenterol., 2005, 100(1), 139-143.
[http://dx.doi.org/10.1111/j.1572-0241.2005.41000.x] [PMID: 15654793]
[65]
Botteri, E.; Iodice, S.; Raimondi, S.; Maisonneuve, P.; Lowenfels, A.B. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology, 2008, 134(2), 388-395.
[http://dx.doi.org/10.1053/j.gastro.2007.11.007] [PMID: 18242207]
[66]
Zisman, A.L.; Nickolov, A.; Brand, R.E.; Gorchow, A.; Roy, H.K. Associations between the age at diagnosis and location of colorectal cancer and the use of alcohol and tobacco: implications for screening. Arch. Intern. Med., 2006, 166(6), 629-634.
[http://dx.doi.org/10.1001/archinte.166.6.629] [PMID: 16567601]
[67]
Tsong, W.H.; Koh, W.P.; Yuan, J.M.; Wang, R.; Sun, C.L.; Yu, M.C. Cigarettes and alcohol in relation to colorectal cancer: the Singapore Chinese Health Study. Br. J. Cancer, 2007, 96(5), 821-827.
[http://dx.doi.org/10.1038/sj.bjc.6603623] [PMID: 17311023]
[68]
P??schl, G.; Seitz, H.K. Alcohol and cancer. Alcohol Alcohol., 2004, 39(3), 155-165.
[http://dx.doi.org/10.1093/alcalc/agh057] [PMID: 15082451]
[69]
Ries, L.A.G.; Melbert, D.; Krapcho, M.; Stinchcomb, D.G.; Howlader, N.; Horner, M.J.; Mariotto, A. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr. Cancer, 2008, 60, 131-144.
[70]
International Agency for Research on Cancer; Globocan 2018: Cancer Fact Sheets Colorectal Cancer. IARC. http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum- fact-sheet.pdf(2018).
[71]
OƒConnell, J.B.; Maggard, M.A.; Liu, J.H.; Etzioni, D.A.; Livingston, E.H.; Ko, C.Y. Rates of colon and rectal cancers are increasing in young adults. Am. Surg., 2003, 69(10), 866-872.
[PMID: 14570365]
[72]
Fairley, T.L.; Cardinez, C.J.; Martin, J.; Alley, L.; Friedman, C.; Edwards, B.; Jamison, P. Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001. Cancer, 2006, 107(5), S1153-S1161.
[http://dx.doi.org/10.1002/cncr.22012] [PMID: 16862554]
[73]
National Institutes of Health.. What You Need to Know About Cancer of the Colon and Rectum; U.S. Department of Health and Human Services & National Institutes of Health: Bethesda, MD 2006.
[74]
Skibber, J.; Minsky, B.; Hoff, P. Cancer of the colon and rectum.Cancer: Principles & Practice of Oncology, 6th Ed; DeVita, V.T.Jr.; Hellmann, S.; Rosenberg, S.A., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2001, pp. 1216-1271.
[75]
Boardman, L.A.; Morlan, B.W.; Rabe, K.G.; Petersen, G.M.; Lindor, N.M.; Nigon, S.K.; Goldberg, J.; Gallinger, S. Colorectal cancer risks in relatives of young-onset cases: is risk the same across all first-degree relatives? Clin. Gastroenterol. Hepatol., 2007, 5(10), 1195-1198.
[http://dx.doi.org/10.1016/j.cgh.2007.06.001] [PMID: 17702662]
[76]
World Cancer Research Fund and American Institute for Cancer Research.. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective Washington; American Institute for Cancer Research: DC, 2007.
[77]
Bodmer, W.F.; Bailey, C.J.; Bodmer, J.; Bussey, H.J.; Ellis, A.; Gorman, P.; Lucibello, F.C.; Murday, V.A.; Rider, S.H.; Scambler, P. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature, 1987, 328(6131), 614-616.
[http://dx.doi.org/10.1038/328614a0] [PMID: 3039373]
[78]
Grady, W.M. Genetic testing for high-risk colon cancer patients. Gastroenterology, 2003, 124(6), 1574-1594.
[http://dx.doi.org/10.1016/S0016-5085(03)00376-7] [PMID: 12761718]
[79]
Goss, K.H.; Groden, J. Biology of the adenomatous polyposis coli tumor suppressor. J. Clin. Oncol., 2000, 18(9), 1967-1979.
[http://dx.doi.org/10.1200/JCO.2000.18.9.1967] [PMID: 10784639]
[80]
Yamulla, R.J.; Kane, E.G.; Moody, A.E.; Politi, K.A.; Lock, N.E.; Foley, A.V.; Roberts, D.M. Testing models of the APC tumor suppressor ý-catenin interaction reshapes our view of the destruction complex in Wnt signaling. Genetics, 2014, 197(4), 1285-1302.
[http://dx.doi.org/10.1534/genetics.114.166496] [PMID: 24931405]
[81]
van der Flier, L.G.; Clevers, H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu. Rev. Physiol., 2009, 71, 241-260.
[http://dx.doi.org/10.1146/annurev.physiol.010908.163145] [PMID: 18808327]
[82]
Gammon, A.; Kohlmann, W.; Burt, R. Can we identify the high-risk patients to be screened A genetic approach? Digestion, 2007, 76, 7-19.
[http://dx.doi.org/10.1159/000108389]
[83]
Lipton, L.; Halford, S.E.; Johnson, V.; Novelli, M.R.; Jones, A.; Cummings, C.; Barclay, E.; Sieber, O.; Sadat, A.; Bisgaard, M.L.; Hodgson, S.V.; Aaltonen, L.A.; Thomas, H.J.; Tomlinson, I.P. Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. Cancer Res., 2003, 63(22), 7595-7599.
[PMID: 14633673]
[84]
Al-Sohaily, S.; Biankin, A.; Leong, R.; Kohonen-Corish, M.; Warusavitarne, J. Molecular pathways in colorectal cancer. J. Gastroenterol. Hepatol., 2012, 27(9), 1423-1431.
[http://dx.doi.org/10.1111/j.1440-1746.2012.07200.x] [PMID: 22694276]
[85]
Desai, T.K.; Barkel, D. Syndromic colon cancer: lynch syndrome and familial adenomatous polyposis. Gastroenterol. Clin. North Am., 2008, 37(1), 47-72.
[http://dx.doi.org/10.1016/j.gtc.2007.12.006] [PMID: 18313539]
[86]
Stoffel, E.; Mukherjee, B.; Raymond, V.M.M.; Tayob, N.; Kastrinos, F.; Sparr, J. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology, 2009, 137(5), 1621-1627.
[87]
Jasperson, K.W. Genetic testing by cancer site: colon (polyposis syndromes). Cancer J., 2012, 18(4), 328-333.
[http://dx.doi.org/10.1097/PPO.0b013e3182609300] [PMID: 22846733]
[88]
Shimamoto, Y.; Yamaguchi, M. HTLV-I induced extranodal lymphomas. Leuk. Lymphoma, 1992, 7(1-2), 37-45.
[http://dx.doi.org/10.3109/10428199209053600] [PMID: 1472932]
[89]
Sweet, K.; Willis, J.; Zhou, X.P.; Gallione, C.; Sawada, T.; Alhopuro, P.; Khoo, S.K.; Patocs, A.; Martin, C.; Bridgeman, S.; Heinz, J.; Pilarski, R.; Lehtonen, R.; Prior, T.W.; Frebourg, T.; Teh, B.T.; Marchuk, D.A.; Aaltonen, L.A.; Eng, C. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA, 2005, 294(19), 2465-2473.
[http://dx.doi.org/10.1001/jama.294.19.2465] [PMID: 16287957]
[90]
Bleuming, S.A.; He, X.C.; Kodach, L.L.; Hardwick, J.C.; Koopman, F.A.; Ten Kate, F.J.; van Deventer, S.J.; Hommes, D.W.; Peppelenbosch, M.P.; Offerhaus, G.J.; Li, L.; van den Brink, G.R. Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice. Cancer Res., 2007, 67(17), 8149-8155.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-4659] [PMID: 17804727]
[91]
Wolf, R.L.; Basch, C.E.; Brouse, C.H.; Shmukler, C.; Shea, S. Patient preferences and adherence to colorectal cancer screening in an urban population. Am. J. Public Health, 2006, 96(5), 809-811.
[http://dx.doi.org/10.2105/AJPH.2004.049684] [PMID: 16571715]
[92]
Rex, D.K.; Johnson, D.A.; Anderson, J.C.; Schoenfeld, P.S.; Burke, C.A.; Inadomi, J.M. American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009. [corrected]. Am. J. Gastroenterol., 2009, 104(3), 739-750.
[http://dx.doi.org/10.1038/ajg.2009.104] [PMID: 19240699]
[93]
Navarro, M.; Nicolas, A.; Ferrandez, A.; Lanas, A. Colorectal cancer population screening programs worldwide in 2016: an update. World J. Gastroenterol., 2017, 23(20), 3632-3642.
[http://dx.doi.org/10.3748/wjg.v23.i20.3632] [PMID: 28611516]
[94]
Lin, J.S.; Piper, M.A.; Perdue, L.A.; Rutter, C.M.; Webber, E.M.; O’Connor, E.; Smith, N.; Whitlock, E.P. Screening for colorectal cancer: updated evidence report and systematic review for the us preventive services task force. JAMA, 2016, 315(23), 2576-2594.
[http://dx.doi.org/10.1001/jama.2016.3332] [PMID: 27305422]
[95]
Rex, D.K.; Boland, C.R.; Dominitz, J.A.; Giardiello, F.M.; Johnson, D.A.; Kaltenbach, T.; Levin, T.R.; Lieberman, D.; Robertson, D.J. Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer. Gastroenterology, 2017, 153(1), 307-323.
[http://dx.doi.org/10.1053/j.gastro.2017.05.013] [PMID: 28600072]
[96]
Saito, H. Colorectal cancer screening using immunochemical faecal occult blood testing in Japan. J. Med. Screen., 2006, 13, S6-S7.
[PMID: 17227634]
[97]
Schoen, R.E.; Pinsky, P.F.; Weissfeld, J.L.; Yokochi, L.A.; Church, T.; Laiyemo, A.O.; Bresalier, R.; Andriole, G.L.; Buys, S.S.; Crawford, E.D.; Fouad, M.N.; Isaacs, C.; Johnson, C.C.; Reding, D.J.; O’Brien, B.; Carrick, D.M.; Wright, P.; Riley, T.L.; Purdue, M.P.; Izmirlian, G.; Kramer, B.S.; Miller, A.B.; Gohagan, J.K.; Prorok, P.C.; Berg, C.D. PLCO project team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N. Engl. J. Med., 2012, 366(25), 2345-2357.
[http://dx.doi.org/10.1056/NEJMoa1114635] [PMID: 22612596]
[98]
Hewitson, P.; Glasziou, P.; Watson, E.; Towler, B.; Irwig, L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am. J. Gastroenterol., 2008, 103(6), 1541-1549.
[http://dx.doi.org/10.1111/j.1572-0241.2008.01875.x] [PMID: 18479499]
[99]
Brenner, H.; Chang-Claude, J.; Seiler, C.M.; Rickert, A.; Hoffmeister, M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann. Intern. Med., 2011, 154(1), 22-30.
[http://dx.doi.org/10.7326/0003-4819-154-1-201101040-00004] [PMID: 21200035]
[100]
Pickhardt, P.J.; Hassan, C.; Halligan, S.; Marmo, R. Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis. Radiology, 2011, 259(2), 393-405.
[http://dx.doi.org/10.1148/radiol.11101887] [PMID: 21415247]
[101]
Vakiani, E.; Yantiss, R.K. Pathologic features and biologic importance of colorectal serrated polyps. Adv. Anat. Pathol., 2009, 16(2), 79-91.
[http://dx.doi.org/10.1097/PAP.0b013e31819923b3] [PMID: 19550369]
[102]
Knudsen, A.B.; Zauber, A.G.; Rutter, C.M.; Naber, S.K.; Doria-Rose, V.P.; Pabiniak, C.; Johanson, C.; Fischer, S.E.; Lansdorp-Vogelaar, I.; Kuntz, K.M. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modelling study for the US preventive services task force. JAMA, 2016, 315(23), 2595-2609.
[http://dx.doi.org/10.1001/jama.2016.6828] [PMID: 27305518]
[103]
Wolf, A.M.D.; Fontham, E.T.H.; Church, T.R.; Flowers, C.R.; Guerra, C.E.; LaMonte, S.J.; Etzioni, R.; McKenna, M.T.; Oeffinger, K.C.; Shih, Y.T.; Walter, L.C.; Andrews, K.S.; Brawley, O.W.; Brooks, D.; Fedewa, S.A.; Manassaram-Baptiste, D.; Siegel, R.L.; Wender, R.C.; Smith, R.A. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J. Clin., 2018, 68(4), 250-281.
[http://dx.doi.org/10.3322/caac.21457] [PMID: 29846947]
[104]
Mulder, W.J.; Griffioen, A.W.; Strijkers, G.J.; Cormode, D.P.; Nicolay, K.; Fayad, Z.A. Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine (Lond.), 2007, 2(3), 307-324.
[http://dx.doi.org/10.2217/17435889.2.3.307] [PMID: 17716176]
[105]
He, X.; Liu, F.; Liu, L.; Duan, T.; Zhang, H.; Wang, Z. Lectin-conjugated Fe2O3@Au core@Shell nanoparticles as dual mode contrast agents for in vivo detection of tumor. Mol. Pharm., 2014, 11(3), 738-745.
[http://dx.doi.org/10.1021/mp400456j] [PMID: 24472046]
[106]
Gounaris, E.; Martin, J.; Ishihara, Y.; Khan, M.W.; Lee, G.; Sinh, P.; Chen, E.Z.; Angarone, M.; Weissleder, R.; Khazaie, K.; Barrett, T.A. Fluorescence endoscopy of cathepsin activity discriminates dysplasia from colitis. Inflamm. Bowel Dis., 2013, 19(7), 1339-1345.
[http://dx.doi.org/10.1097/MIB.0b013e318281f3f8] [PMID: 23591598]
[107]
Butel, M.J.; Roland, N.; Hibert, A.; Popot, F.; Favre, A.; Tessedre, A.C.; Bensaada, M.; Rimbault, A.; Szylit, O. Clostridial pathogenicity in experimental necrotising enterocolitis in gnotobiotic quails and protective role of bifidobacteria. J. Med. Microbiol., 1998, 47(5), 391-399.
[http://dx.doi.org/10.1099/00222615-47-5-391] [PMID: 9879939]
[108]
Kalyani, N.K.; Kharb, S.; Thompkinson, D.K. Inulin dietary fiber with functional and health attributes-a review. Food Rev. Int., 2010, 6, 189-203.
[http://dx.doi.org/10.1080/87559121003590664]
[109]
Gibson, G.R.; Beatty, E.R.; Wang, X.; Cummings, J.H. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology, 1995, 108(4), 975-982.
[http://dx.doi.org/10.1016/0016-5085(95)90192-2] [PMID: 7698613]
[110]
The Declaration of Certain Isolated or Synthetic Non-Digestible Carbohydrates as Dietary Fiber on Nutrition and Supplement Facts Labels.United States Food and Drug Administration, Guidance for Industry; Availability, 2018, pp. 1-8.
[111]
Mensink, M.A.; Frijlink, H.W.; van der Voort Maarschalk, K.; Hinrichs, W.L.J. Inulin, a flexible oligosaccharide I: review of its physicochemical characteristics. Carbohydr. Polym., 2015, 130, 405-419.
[http://dx.doi.org/10.1016/j.carbpol.2015.05.026] [PMID: 26076642]
[112]
Koruri, S.S.; Banerjee, D.; Chowdhury, R.; Bhattacharya, P. Studies on prebiotic food additive (inulin) in Indian dietary fibre sources - Garlic (Allium sativum), Wheat (Triticum spp.), oat (Avena sativa) and dalia (Bulgur). Int. J. Pharma Sci., 2014, 6, 278-282.
[113]
Leite, J.T.C.; Morr, F.E.X.; Martinelli, P.; Dal Fabbro, I.M.; Park, K.J. Optimization of a physical concentration process for inulin. J. Food Eng., 2007, 80, 832-838.
[http://dx.doi.org/10.1016/j.jfoodeng.2006.07.012]
[114]
Belval, H. Industrie de l‘inuline et du le’vulose. Dix ans dƒ??efforts scientifiques; industriels et coloniaux.Adv. Food Nutr. Res; , 1927, pp. 1068-1069.
[115]
Crittenden, R.; Planyne, M. Production, properties and applications of food grade oligosaccharides. Trends Food Sci. Technol., 1996, 7, 357.
[http://dx.doi.org/10.1016/S0924-2244(96)10038-8]
[116]
Heyer, A.G.; Schroeer, B.; Radosta, S.; Wolff, D.; Czapla, S.; Springer, J. Structure of the enzymatically synthesized fructan inulin. Carbohydr. Res., 1998, 313(3-4), 165-174.
[http://dx.doi.org/10.1016/S0008-6215(98)00281-X] [PMID: 10209864]
[117]
Ronkart, S.; Deroanne, N.; Paqout, C.; Fougnies, M.; Lambrechts, C.J.C.; Blecker, C.S. Characterization of the physical state of spray-dried inulin. Food Biophys., 2007, 2, 83-92.
[http://dx.doi.org/10.1007/s11483-007-9034-7]
[118]
Ozimek, L.K.; Kralj, S.; van der Maarel, M.J.; Dijkhuizen, L. The levansucrase and inulosucrase enzymes of Lactobacillus reuteri 121 catalyse processive and non-processive transglycosylation reactions. Microbiology, 2006, 152(Pt 4), 1187-1196.
[http://dx.doi.org/10.1099/mic.0.28484-0] [PMID: 16549681]
[119]
Wada, T.; Sugatani, J.; Terada, E.; Ohguchi, M.; Miwa, M. Physicochemical characterization and biological effects of inulin enzymatically synthesized from sucrose. J. Agric. Food Chem., 2005, 53(4), 1246-1253.
[http://dx.doi.org/10.1021/jf048711u] [PMID: 15713048]
[120]
Hellwege, E.M.; Czapla, S.; Jahnke, A.; Willmitzer, L.; Heyer, A.G. Transgenic potato (Solanum tuberosum) tubers synthesize the full spectrum of inulin molecules naturally occurring in globe artichoke (Cynara scolymus) roots. Proc. Natl. Acad. Sci. USA, 2000, 97(15), 8699-8704.
[http://dx.doi.org/10.1073/pnas.150043797] [PMID: 10890908]
[121]
Petkova, N.; Ognyanov, M.; Denev, P. Academy of isolation and characterization of inulin obtained from taproot of common chicory, Chicoriumintybus L.Bulgaria Scientific Paper; , 2014, 39, pp. 25-34.
[122]
Lis, D.G.; Preston, L.A.U.S. Patent No. 5,840,884. Washington, D.C.; U.S Patent and Trademark Office, 1998.
[123]
U.S. Patent No.5, 840, 884.Washington, D.C.; U.S Patent and Trademark Office.
[124]
Marchessault, R.H.; Bleha, T.; Deslandes, Y.; Revol, J.F. Conformation and crystalline structure of (2 1) β-D-fructofuranan (inulin). Can. J. Chem., 1980, 58, 2415-2422.
[http://dx.doi.org/10.1139/v80-390]
[125]
André, I.; Putaux, J.L.; Chanzy, H.; Taravel, F.R.; Timmermans, J.W.; de Wit, D. Single crystals of inulin. Int. J. Biol. Macromol., 1996, 18(3), 195-204.
[http://dx.doi.org/10.1016/0141-8130(95)01075-0] [PMID: 8729031]
[126]
Turner, E.; Munro, A.G.; Comfort, P. Female soccer: Part 1- A needs analysis. Strength Condit. J., 2013, 35(1), 51-57.
[127]
Kim, D.; Robyt, J.F.; Lee, S.Y.; Lee, J.H.; Kim, Y.M. Dextran molecular size and degree of branching as a function of sucrose concentration, pH, and temperature of reaction of Leuconostoc mesenteroides B-512FMCM dextransucrase. Carbohydr. Res., 2003, 338(11), 1183-1189.
[http://dx.doi.org/10.1016/S0008-6215(03)00148-4] [PMID: 12747860]
[128]
Leyva, P.C.; LÓpez, P.A.L.; Alvarez, S.C.; Pére, U.C.; Leos, Z.S. Physical properties of inulin and technological applications.Polysacch. Bioactivity Biotechnol; , 2015, pp. 959-984.
[129]
Nwafor, I.C.; Shale, K.; Achilonu, M.C. Chemical composition and nutritive benefits of chicory (Cichorium intybus) as an ideal complementary and/or alternative livestock feed supplement. ScientificWorldJournal, 2017, 2017 7343928
[http://dx.doi.org/10.1155/2017/7343928] [PMID: 29387778]
[130]
Alvarez, F.P.P.; Jurado, T.B.; Calixto, C.M.; Incio, V.N.; Silva, A.J. Prebiotic inulin/oligofructose in Yacun root (Smallanthus sonchifolius), phytochemistry and standardization as basis for clinical and pre-clinical research. Rev. Gastroenterol. Peru, 2008, 28(1), 22-27.
[PMID: 18418450]
[131]
Hague, A.; Manning, A.M.; Hanlon, K.A.; Huschtscha, L.I.; Hart, D.; Paraskeva, C. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int. J. Cancer, 1993, 55(3), 498-505.
[http://dx.doi.org/10.1002/ijc.2910550329] [PMID: 8397167]
[132]
van Loo, J.; Coussement, P.; de Leenheer, L.; Hoebregs, H.; Smits, G. On the presence of inulin and oligofructose as natural ingredients in the western diet. Crit. Rev. Food Sci. Nutr., 1995, 35(6), 525-552.
[http://dx.doi.org/10.1080/10408399509527714] [PMID: 8777017]
[133]
Kruh, J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell. Biochem., 1982, 42(2), 65-82.
[PMID: 6174854]
[134]
Candela, M.; Turroni, S.; Biagi, E.; Carbonero, F.; Rampelli, S.; Fiorentini, C.; Brigidi, P. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J. Gastroenterol., 2014, 20(4), 908-922.
[http://dx.doi.org/10.3748/wjg.v20.i4.908] [PMID: 24574765]
[135]
Medzhitov, R. Origin and physiological roles of inflammation. Nature, 2008, 454(7203), 428-435.
[http://dx.doi.org/10.1038/nature07201] [PMID: 18650913]
[136]
Grivennikov, S.I.; Karin, M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev., 2010, 21(1), 11-19.
[http://dx.doi.org/10.1016/j.cytogfr.2009.11.005] [PMID: 20018552]
[137]
Keku, T.O.; Dulal, S.; Deveaux, A.; Jovov, B.; Han, X. The gastrointestinal microbiota and colorectal cancer. Am. J. Physiol. Gastrointest. Liver Physiol., 2015, 308(5), G351-G363.
[http://dx.doi.org/10.1152/ajpgi.00360.2012] [PMID: 25540232]
[138]
Greten, F.R.; Eckmann, L.; Greten, T.F.; Park, J.M.; Li, Z.W.; Egan, L.J.; Kagnoff, M.F.; Karin, M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 2004, 118(3), 285-296.
[http://dx.doi.org/10.1016/j.cell.2004.07.013] [PMID: 15294155]
[139]
Tian, J.; Lin, X.; Zhou, W.; Xu, J. Hydroxyethyl starch inhibits NF-kappaB activation and prevents the expression of inflammatory mediators in endotoxic rats. Ann. Clin. Lab. Sci., 2003, 33(4), 451-458.
[PMID: 14584760]
[140]
Karrasch, T.; Kim, J.S.; Muhlbauer, M.; Magness, S.T.; Jobin, C. Gnotobiotic IL-10-/-; NF-kappa B(EGFP) mice reveal the critical role of TLR/NF-kappa B signaling in commensal bacteria-induced colitis. J. Immunol., 2007, 178(10), 6522-6532.
[http://dx.doi.org/10.4049/jimmunol.178.10.6522] [PMID: 17475882]
[141]
Tomasello, G.; Tralongo, P.; Damiani, P.; Sinagra, E.; Di Trapani, B.; Zeenny, M.N.; Hussein, I.H.; Jurjus, A.; Leone, A. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes. World J. Gastroenterol., 2014, 20(48), 18121-18130.
[http://dx.doi.org/10.3748/wjg.v20.i48.18121] [PMID: 25561781]
[142]
Macfarlane, G.T.; Macfarlane, S. Bacteria, colonic fermentation, and gastrointestinal health. J. AOAC Int., 2012, 95(1), 50-60.
[http://dx.doi.org/10.5740/jaoacint.SGE_Macfarlane] [PMID: 22468341]
[143]
Flamm, G.; Glinsmann, W.; Kritchevsky, D.; Prosky, L.; Roberfroid, M. Inulin and oligofructose as dietary fiber: a review of the evidence. Crit. Rev. Food Sci. Nutr., 2001, 41(5), 353-362.
[http://dx.doi.org/10.1080/20014091091841] [PMID: 11497328]
[144]
Lee, S.H.; Bajracharya, R.; Min, J.Y.; Han, J.W.; Park, B.J.; Han, H.K. Strategic approaches for colon targeted drug delivery: an overview of recent advancements. Pharmaceutics, 2020, 12(1), 68.
[http://dx.doi.org/10.3390/pharmaceutics12010068] [PMID: 31952340]
[145]
Akala, E.O.; Elekwachi, O.; Chase, V.; Johnson, H.; Lazarre, M.; Scott, K. Organic redox-initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery. Drug Dev. Ind. Pharm., 2003, 29(4), 375-386.
[http://dx.doi.org/10.1081/DDC-120018373] [PMID: 12737531]
[146]
Chourasia, M.K.; Jain, S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci., 2003, 6(1), 33-66.
[PMID: 12753729]
[147]
Zaniboni, A.; Labianca, R.; Gruppo, I. Gruppo Italiano per lo studio e la cura dei tumori del digerente. Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann. Oncol., 2004, 15(9), 1310-1318.
[http://dx.doi.org/10.1093/annonc/mdh342] [PMID: 15319235]
[148]
Schrag, D.; Rifas-Shiman, S.; Saltz, L.; Bach, P.B.; Begg, C.B. Adjuvant chemotherapy use for medicare beneficiaries with stage II colon cancer. J. Clin. Oncol., 2002, 20(19), 3999-4005.
[http://dx.doi.org/10.1200/JCO.2002.11.084] [PMID: 12351597]
[149]
Noordhuis, P.; Holwerda, U.; Van der Wilt, C.L.; Van Groeningen, C.J.; Smid, K.; Meijer, S.; Pinedo, H.M.; Peters, G.J. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann. Oncol., 2004, 15(7), 1025-1032.
[http://dx.doi.org/10.1093/annonc/mdh264] [PMID: 15205195]
[150]
Moertel, C.G. Chemotherapy for colorectal cancer. N. Engl. J. Med., 1994, 330(16), 1136-1142.
[http://dx.doi.org/10.1056/NEJM199404213301608] [PMID: 8133857]
[151]
Douillard, J.Y.; Cunningham, D.; Roth, A.D.; Navarro, M.; James, R.D.; Karasek, P.; Jandik, P.; Iveson, T.; Carmichael, J.; Alakl, M.; Gruia, G.; Awad, L.; Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 2000, 355(9209), 1041-1047.
[http://dx.doi.org/10.1016/S0140-6736(00)02034-1] [PMID: 10744089]
[152]
Watts, P.; Illum, L. Colonic drug delivery. Drug Dev. Ind. Pharm., 1997, 23, 893-913.
[http://dx.doi.org/10.3109/03639049709148695]
[153]
Wood, E.; Wilson, C.G.; Hardy, J.G. The spreading of foam and solution enemas. Int. J. Pharm., 1985, 25, 191-197.
[http://dx.doi.org/10.1016/0378-5173(85)90092-4]
[154]
Chien, Y.W. Oral drug delivery and delivery systems; Novel Drug Del. Sys, 1992, pp. 139-196.
[155]
Ashord, M.; Fell, J.; Attwood, D.; Sharma, H.; Woodhead, P. An evaluation of pectin as a carrier for drug targeting to the colon. J. Control. Release, 1993, 26, 213-220.
[http://dx.doi.org/10.1016/0168-3659(93)90188-B]
[156]
Fukui, E.; Miyamura, N.; Kobayashi, M. An in vitro investigation of the suitability of press-coated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydrophobic additives in the outer shell for colon targeting. J. Control. Release, 2001, 70(1-2), 97-107.
[http://dx.doi.org/10.1016/S0168-3659(00)00332-1] [PMID: 11166411]
[157]
Vassallo, M.; Camilleri, M.; Phillips, S.F.; Brown, M.L.; Chapman, N.J.; Thomforde, G.M. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology, 1992, 102(1), 102-108.
[http://dx.doi.org/10.1016/0016-5085(92)91789-7] [PMID: 1727743]
[158]
Rubinstein, A. Microbially controlled drug delivery to the colon. Biopharm. Drug Dispos., 1990, 11(6), 465-475.
[http://dx.doi.org/10.1002/bdd.2510110602] [PMID: 2207298]
[159]
Cummings, J.H.; Englyst, H.N. Fermentation in the human large intestine and the available substrates. Am. J. Clin. Nutr., 1987, 45(5), S1243-S1255.
[http://dx.doi.org/10.1093/ajcn/45.5.1243] [PMID: 3034048]
[160]
Basit, A.; Bloor, J. Perspectives on colonic drug delivery, business briefing.Pharm. Tech; , 2003, pp. 185-190.
[161]
Park, K.; Shalaby, W.S.W.; Park, H. Biodegradation in: Biodegradable hydrogels in drug delivery. Adv. Drug Deliv. Rev., 1993, 11, 13-34.
[162]
Friend, D.R.; Chang, G.W. Drug glycosides: potential prodrugs for colon-specific drug delivery. J. Med. Chem., 1985, 28(1), 51-57.
[http://dx.doi.org/10.1021/jm00379a012] [PMID: 3965714]
[163]
Sinha, V.R.; Kumria, R. Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci., 2003, 18(1), 3-18.
[http://dx.doi.org/10.1016/S0928-0987(02)00221-X] [PMID: 12554067]
[164]
Van den Mooter, G.; Samyn, C.; Kinget, R. In vivo evaluation of a colon-specific drug delivery system: an absorption study of theophylline from capsules coated with azo polymers in rats. Pharm. Res., 1995, 12(2), 244-247.
[http://dx.doi.org/10.1023/A:1016283027139] [PMID: 7784340]
[165]
Yun, Y.H.; Lee, B.K.; Park, K. Controlled drug delivery: historical perspective for the next generation. J. Control. Release, 2015, 219, 2-7.
[http://dx.doi.org/10.1016/j.jconrel.2015.10.005] [PMID: 26456749]
[166]
Lopez-Molina, D.; Chazarra, S.; How, C.W.; Pruidze, N. Navarro-Pere¬n, E.; Garcia-Ce¬novas, F.; Garcia-Ruiz, P.A.; Rojas-Melgarejo, F.; Rodriguez-Lopez, J.N. Cinnamate of inulin as a vehicle for delivery of colonic drugs. Int. J. Pharm., 2015, 479(1), 96-102.
[http://dx.doi.org/10.1016/j.ijpharm.2014.12.064] [PMID: 25550210]
[167]
Afinjuomo, F.; Barclay, T.G.; Song, Y.; Parikh, A.; Petrovsky, N.; Garg, S.; Parikh, A. Synthesis and characterization of a novel inulin hydrogel crosslinked with pyromellitic dianhydride. React. Funct. Polym., 2019, 4, 104-111.
[http://dx.doi.org/10.1016/j.reactfunctpolym.2018.10.014]
[168]
Van den Mooter, G.; Vervoort, L.; Kinget, R. Characterization of methacrylated inulin hydrogels designed for colon targeting: in vitro release of BSA. Pharm. Res., 2003, 20(2), 303-307.
[http://dx.doi.org/10.1023/A:1022295725841] [PMID: 12636172]
[169]
Licciardi, M.; Scialabba, C.; Sardo, C.; Cavallaro, G.; Giammona, G. Amphiphilic inulin graft co-polymers as self-assembling micelles for doxorubicin delivery. J. Mater. Chem. B Mater. Biol. Med., 2014, 2(27), 4262-4271.
[http://dx.doi.org/10.1039/C4TB00235K] [PMID: 32261564]
[170]
Muley, P.; Kumar, S.; El Kourati, F.; Kesharwani, S.S.; Tummala, H. Hydrophobically modified inulin as an amphiphilic carbohydrate polymer for micellar delivery of paclitaxel for intravenous route. Int. J. Pharm., 2016, 500(1-2), 32-41.
[http://dx.doi.org/10.1016/j.ijpharm.2016.01.005] [PMID: 26792170]
[171]
Essien, H.; Lai, J.Y.; Hwang, K.J. Synthesis of diethylenetriaminepentaacetic acid conjugated inulin and utility for cellular uptake of liposomes. J. Med. Chem., 1988, 31(5), 898-901.
[http://dx.doi.org/10.1021/jm00400a002] [PMID: 3361577]
[172]
Li Volsi, A.; Jimenez de Aberasturi, D.; Henriksen-Lacey, M.; Giammona, G.; Licciardi, M. Liz-Marzi¬n, L.M.Y. Inulin coated plasmonic gold nanoparticles as a tumor-selective tool for cancer therapy. J. Mater. Chem. B Mater. Biol. Med., 2016, 4(6), 1150-1155.
[http://dx.doi.org/10.1039/C5TB01810B] [PMID: 28261481]
[173]
Zhang, L.; Li, Y.; Wang, C.; Li, G.; Zhao, Y.; Yang, Y. Synthesis of methylprednisolone loaded ibuprofen modified inulin based nanoparticles and their application for drug delivery. Mater. Sci. Eng. C, 2014, 42, 111-115.
[http://dx.doi.org/10.1016/j.msec.2014.05.025] [PMID: 25063099]
[174]
Torchilin, V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release, 2001, 73(2-3), 137-172.
[http://dx.doi.org/10.1016/S0168-3659(01)00299-1] [PMID: 11516494]
[175]
Tripodo, G.; Pasut, G.; Trapani, A.; Mero, A.; Lasorsa, F.M.; Chlapanidas, T.; Trapani, G.; Mandracchia, D. Inulin-D-α-tocopherol succinate (INVITE) nanomicelles as a platform for effective intravenous administration of curcumin. Biomacromolecules, 2015, 16(2), 550-557.
[http://dx.doi.org/10.1021/bm501616e] [PMID: 25543760]
[176]
Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release, 2001, 74(1-3), 47-61.
[http://dx.doi.org/10.1016/S0168-3659(01)00309-1] [PMID: 11489482]
[177]
Schoener, C.A.; Carillo-Conde, B.; Hutson, H.N.; Peppas, N.A. An inulin and doxorubicin conjugate for improving cancer therapy. J. Drug Deliv. Sci. Technol., 2013, 23(2), 111-118.
[http://dx.doi.org/10.1016/S1773-2247(13)50018-9] [PMID: 24734120]
[178]
Mauro, N.; Campora, C.; Scialabba, G.; Adamo, M.; Licciardi, G.; Ghersi, G. Self-organized environment-sensitive inulin-doxorubicin conjugate with a selective cytotoxic effect towards cancer cells. RSC Advances, 2015, 41, 421-430.
[http://dx.doi.org/10.1039/C5RA00287G]
[179]
Visser, M.R.; Baert, L.; Klooster, Gv.; Schueller, L.; Geldof, M.; Vanwelkenhuysen, I.; de Kock, H.; De Meyer, S.; Frijlink, H.W.; Rosier, J.; Hinrichs, W.L. Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240. Eur. J. Pharm. Biopharm., 2010, 74(2), 233-238.
[http://dx.doi.org/10.1016/j.ejpb.2009.10.004] [PMID: 19861163]
[180]
Srinarong, P.; Homellinen, S.; Visser, M.R.; Hinrichs, W.L.; Ketolainen, J.; Frijlink, H.W. Surface active derivative of inulin (Inutec® SP1) is a superior carrier for solid dispersions with a high drug load. J. Pharmceut. Sci., 2011, 100, 2333-2342.
[181]
Laura, M.D.; Mohaca, B.; Roberto, C.; Francesco, C.P.; Gennara, C.; Gaetano, G.; Mariano, L. Multicomponent solid dispersion as a formulation strategy to improve drug permeation: a case study on the anti-colorectal cancer. J. Drug Del. Sci., 2019, 52, 346-354.
[182]
van Drooge, D.J.; Hinrichs, W.L.; Wegman, K.A.; Visser, M.R.; Eissens, A.C.; Frijlink, H.W. Solid dispersions based on inulin for the stabilisation and formulation of delta 9-tetrahydrocannabinol. Eur. J. Pharm. Sci., 2004, 21(4), 511-518.
[http://dx.doi.org/10.1016/j.ejps.2003.11.014] [PMID: 14998582]
[183]
Pitarresi, G.; Tripodo, G.; Calabrese, R.; Craparo, E.F.; Licciardi, M.; Giammona, G. Hydrogels for potential colon drug release by thiolene conjugate addition of a new inulin derivative. Macromol. Biosci., 2008, 8(10), 891-902.
[http://dx.doi.org/10.1002/mabi.200800043] [PMID: 18576285]
[184]
Maris, B.; Verheyden, L.; Van Reeth, K.; Samyn, C.; Augustijns, P.; Kinget, R.; Van den Mooter, G. Synthesis and characterisation of inulin-azo hydrogels designed for colon targeting. Int. J. Pharm., 2001, 213(1-2), 143-152.
[http://dx.doi.org/10.1016/S0378-5173(00)00654-2] [PMID: 11165102]
[185]
Buwalda, S.J.; Boere, K.W.; Dijkstra, P.J.; Feijen, J.; Vermonden, T.; Hennink, W.E. Hydrogels in a historical perspective: from simple networks to smart materials. J. Control. Release, 2014, 190, 254-273.
[http://dx.doi.org/10.1016/j.jconrel.2014.03.052] [PMID: 24746623]
[186]
Damian, F.; Van den Mooter, G.; Samyn, C.; Kinget, R. In vitro biodegradation study of acetyl and methyl inulins by Bifidobacteria and inulinase. Eur. J. Pharm. Biopharm., 1999, 47(3), 275-282.
[http://dx.doi.org/10.1016/S0939-6411(99)00007-7] [PMID: 10382112]
[187]
Tripodo, G.; Pitarresi, G.; Cavallaro, G.; Palumbo, F.S.; Giammona, G. Controlled release of IgG by novel UV induced polysaccharide/poly(amino acid) hydrogels. Macromol. Biosci., 2009, 9(4), 393-401.
[http://dx.doi.org/10.1002/mabi.200800181] [PMID: 19003848]
[188]
Castelli, F.; Sarpietro, M.G.; Micieli, D.; Ottimo, S.; Pitarresi, G.; Tripodo, G.; Carlisi, B.; Giammona, G. Differential scanning calorimetry study on drug release from an inulin-based hydrogel and its interaction with a biomembrane model: pH and loading effect. Eur. J. Pharm. Sci., 2008, 35(1-2), 76-85.
[http://dx.doi.org/10.1016/j.ejps.2008.06.005] [PMID: 18619534]
[189]
Petrovsky, N.; Aguilar, J.C. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol., 2004, 82(5), 488-496.
[http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x] [PMID: 15479434]
[190]
Rock, K.L.; Hearn, A.; Chen, C.J.; Shi, Y. Natural endogenous adjuvants. Springer Semin. Immunopathol., 2005, 26(3), 231-246.
[http://dx.doi.org/10.1007/s00281-004-0173-3] [PMID: 15609001]
[191]
Hinrichs, W.L.; Prinsen, M.G.; Frijlink, H.W. Inulin glasses for the stabilization of therapeutic proteins. Int. J. Pharm., 2001, 215(1-2), 163-174.
[http://dx.doi.org/10.1016/S0378-5173(00)00677-3] [PMID: 11250102]
[192]
Audouy, S.A.; van der Schaaf, G.; Hinrichs, W.L.; Frijlink, H.W.; Wilschut, J.; Huckriede, A. Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine, 2011, 29(26), 4345-4352.
[http://dx.doi.org/10.1016/j.vaccine.2011.04.029] [PMID: 21514345]
[193]
Cooper, P.D. Vaccine adjuvants based on gamma inulin. Pharm. Biotechnol., 1995, 6, 559-580.
[http://dx.doi.org/10.1007/978-1-4615-1823-5_24] [PMID: 7551236]
[194]
Cooper, P.D.; Petrovsky, N. Delta inulin: a novel, immunologically active, stable packing structure comprising? ý-D-[2 -> 1] poly(fructo-furanosyl) α-D-glucose polymers. Glycobiology, 2011, 21(5), 595-606.
[http://dx.doi.org/10.1093/glycob/cwq201] [PMID: 21147758]
[195]
de Jonge, J.; Amorij, J.P.; Hinrichs, W.L.; Wilschut, J.; Huckriede, A.; Frijlink, H.W. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur. J. Pharm. Sci., 2007, 32(1), 33-44.
[http://dx.doi.org/10.1016/j.ejps.2007.05.112] [PMID: 17628452]
[196]
Singh, M.; O’Hagan, D.T. Recent advances in veterinary vaccine adjuvants. Int. J. Parasitol., 2003, 33(5-6), 469-478.
[http://dx.doi.org/10.1016/S0020-7519(03)00053-5] [PMID: 12782048]
[197]
Furrie, E.; Smith, R.E.; Turner, M.W.; Strobel, S.; Mowat, A.M. Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of Immune Stimulating Complexes (ISCOMS). Vaccine, 2002, 20(17-18), 2254-2262.
[http://dx.doi.org/10.1016/S0264-410X(02)00106-8] [PMID: 12009281]
[198]
Gilbert, S.C.; Plebanski, M.; Harris, S.J.; Allsopp, C.E.M.; Thomas, R.; Layton, G.T.; Hill, A.V.S. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol., 1997, 15(12), 1280-1284.
[http://dx.doi.org/10.1038/nbt1197-1280] [PMID: 9359112]
[199]
Allsopp, C.E.; Plebanski, M.; Gilbert, S.; Sinden, R.E.; Harris, S.; Frankel, G.; Dougan, G.; Hioe, C.; Nixon, D.; Paoletti, E.; Layton, G.; Hill, A.V. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol., 1996, 26(8), 1951-1959.
[http://dx.doi.org/10.1002/eji.1830260841] [PMID: 8765044]
[200]
Gamvrellis, A.; Leong, D.; Hanley, J.C.; Xiang, S.D.; Mottram, P.; Plebanski, M. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol., 2004, 82(5), 506-516.
[http://dx.doi.org/10.1111/j.0818-9641.2004.01271.x] [PMID: 15479436]
[201]
Silva, D.G.; Cooper, P.D.; Petrovsky, N. Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunol. Cell Biol., 2004, 82(6), 611-616.
[http://dx.doi.org/10.1111/j.1440-1711.2004.01290.x] [PMID: 15550119]
[202]
Scialabba, C.; Licciardi, M.; Mauro, N.; Rocco, F.; Ceruti, M.; Giammona, G. Inulin-based polymer coated SPIONs as potential drug delivery systems for targeted cancer therapy. Eur. J. Pharm. Biopharm., 2014, 88(3), 695-705.
[http://dx.doi.org/10.1016/j.ejpb.2014.09.008] [PMID: 25281781]
[203]
van der Meel, R.; Vehmeijer, L.J.C.; Kok, R.J.; Storm, G.; van Gaal, E.V.B. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv. Drug Deliv. Rev., 2013, 65(10), 1284-1298.
[http://dx.doi.org/10.1016/j.addr.2013.08.012] [PMID: 24018362]
[204]
Pissuwan, D.; Niidome, T.; Cortie, M.B.J. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J. Control. Release, 2011, 149(1), 65-71.
[http://dx.doi.org/10.1016/j.jconrel.2009.12.006] [PMID: 20004222]
[205]
Aberasturi, D.J.D.; Serrano, M.A.B.; Liz Marzan, L.M. Modern applications of plasmonic nanoparticles: from energy to health. Adv. Opt. Mater., 2015, 3, 602-617.
[http://dx.doi.org/10.1002/adom.201500053]
[206]
Giner-Casares, J.J.; Henriksen-Lacey, M.; Coronado-Puchau, M.; Liz-Marzan, L.M. Inorganic nanoparticles for biomedicine: where materials scientists meet medical research. Mater. Today, 2016, 19, 19-28.
[http://dx.doi.org/10.1016/j.mattod.2015.07.004]
[207]
Grzelczak, M. Liz-Marz?¬n, L.M. Colloidal nanoplasmonics: from building blocks to sensing devices. Langmuir, 2013, 29(15), 4652-4663.
[http://dx.doi.org/10.1021/la4001544] [PMID: 23421758]
[208]
Lista, M.; Liu, D.Z.; Mulvaney, P. Phase transfer of noble metal nanoparticles to organic solvents. Langmuir, 2014, 30(8), 1932-1938.
[http://dx.doi.org/10.1021/la404569h] [PMID: 24479856]
[209]
Serrano-Montes, A.B.; Jimenez de Aberasturi, D.; Langer, J.; Giner-Casares, J.J.; Scarabelli, L.; Herrero, A.; Liz-Marzán, L.M. A general method for solvent exchange of plasmonic nanoparticles and self-assembly into SERS-active monolayers. Langmuir, 2015, 31(33), 9205-9213.
[http://dx.doi.org/10.1021/acs.langmuir.5b01838] [PMID: 26258732]
[210]
Soliman, M.G.; Pelaz, B.; Wolfgang, J.P.S.; Pino, P. Phase transfer and polymer coating methods toward improving the stability of metallic nanoparticles for biological applications. Chem. Mater., 2015, 27, 990-997.
[http://dx.doi.org/10.1021/cm5043167]
[211]
Zhao, Y.; Butler, E.B.; Tan, M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis., 2013, 4, e532
[http://dx.doi.org/10.1038/cddis.2013.60] [PMID: 23470539]
[212]
Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem., 2010, 21(5), 797-802.
[http://dx.doi.org/10.1021/bc100070g] [PMID: 20397686]
[213]
Bamodu, O.A.; Huang, W.C.; Tzeng, D.T.; Wu, A.; Wang, L.S.; Yeh, C.T.; Chao, T.Y. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity. Cancer Lett., 2015, 364(2), 125-134.
[http://dx.doi.org/10.1016/j.canlet.2015.05.006] [PMID: 25976769]

Rights & Permissions Print Cite
Article Metrics
34
© 2024 Bentham Science Publishers | Privacy Policy